NPC1
MCID: NMN015
MIFTS: 67

Niemann-Pick Disease, Type C1 (NPC1)

Categories: Eye diseases, Genetic diseases, Immune diseases, Liver diseases, Metabolic diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Niemann-Pick Disease, Type C1

MalaCards integrated aliases for Niemann-Pick Disease, Type C1:

Name: Niemann-Pick Disease, Type C1 57 13 38 72
Niemann-Pick Disease, Type C 57 75 53 29 6 44 72
Niemann-Pick Disease Type C1 12 53 29 6 15 40
Niemann-Pick Disease, Type D 57 29 6 72
Npc1 57 12 53 74
Neurovisceral Storage Disease with Vertical Supranuclear Ophthalmoplegia 57 53 74
Niemann-Pick Disease with Cholesterol Esterification Block 57 53 74
Niemann-Pick Disease Type C 24 59 37
Niemann-Pick Disease Without Sphingomyelinase Deficiency 57 74
Niemann-Pick Disease, Chronic Neuronopathic Form 57 53
Niemann-Pick Disease, Subacute Juvenile Form 57 53
Niemann-Pick Disease Type D 75 74
Npc 57 74
Niemann-Pick Disease Chronic Neuronopathic Form 74
Niemann-Pick Disease Subacute Juvenile Form 74
Niemann-Pick Disease Nova Scotian Type 74
Niemann-Pick Disease, Type C; Npc 57
Juvenile Niemann-Pick Disease 24
Niemann-Pick Disease Type Ii 74
Niemann-Picks Disease Type C 55
Niemann-Pick C1 Disease 75
Niemann-Pick Disease C1 74

Characteristics:

Orphanet epidemiological data:

59
niemann-pick disease type c
Inheritance: Autosomal recessive; Prevalence: 1-9/100000 (Europe),1-9/1000000 (France),1-9/1000000 (Sweden); Age of onset: All ages;

OMIM:

57
Inheritance:
autosomal recessive

Miscellaneous:
variable phenotype
genetic heterogeneity (see npc2, )
disease usually becomes apparent in early childhood
death usually in teenage years
four major groups: early infantile, late infantile, juvenile, adult
earlier onset associated with faster progression and shorter life span
incidence of 1 in 150,000 live births in the general population
incidence of 1% in yarmouth county, nova scotia
estimated carrier frequency of 10-25% in yarmouth county, nova scotia
nova scotian variant (type d) is considered a genetic isolate of npc1 and is associated with a mutation in the npc1 gene ()


HPO:

32
niemann-pick disease, type c1:
Inheritance autosomal recessive inheritance heterogeneous
Onset and clinical course onset


Classifications:



External Ids:

Disease Ontology 12 DOID:0070113
OMIM 57 257220
KEGG 37 H00136
MeSH 44 D052556
ICD10 33 E75.2
MESH via Orphanet 45 D052556
ICD10 via Orphanet 34 E75.2
UMLS via Orphanet 73 C0220756
Orphanet 59 ORPHA646
UMLS 72 C0220756 C0268247 C3179455

Summaries for Niemann-Pick Disease, Type C1

OMIM : 57 Niemann-Pick type C (NPC) disease is an autosomal recessive lipid storage disorder characterized by progressive neurodegeneration. Approximately 95% of cases are caused by mutations in the NPC1 gene, referred to as type C1; 5% are caused by mutations in the NPC2 gene (601015), referred to as type C2 (607625). The clinical manifestations of types C1 and C2 are similar because the respective genes are both involved in egress of lipids, particularly cholesterol, from late endosomes or lysosomes (summary by Vance, 2006). Historically, Crocker (1961) delineated 4 types of Niemann-Pick disease: the classic infantile form (type A; 257200), the visceral form (type B; 607616), the subacute or juvenile form (type C), and the Nova Scotian variant (type D). Types C1 and D are indistinguishable except for the occurrence of type D in patients of Nova Scotian Acadian ancestry. Since then, types E and F have also been described (see 607616), and phenotypic variation within each group has also been described. (257220)

MalaCards based summary : Niemann-Pick Disease, Type C1, also known as niemann-pick disease, type c, is related to niemann-pick disease, type c2 and niemann-pick disease, and has symptoms including seizures, muscle spasticity and cerebellar ataxia. An important gene associated with Niemann-Pick Disease, Type C1 is NPC1 (NPC Intracellular Cholesterol Transporter 1), and among its related pathways/superpathways are Lysosome and Lipoprotein metabolism. The drugs Miglustat and 1-Deoxynojirimycin have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and bone, and related phenotypes are ataxia and gait disturbance

Disease Ontology : 12 A Niemann-Pick disease that has material basis in an autosomal recessive mutation of NPC1 on chromosome 18q11.2.

NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 646DefinitionNiemann-Pick disease type C (NP-C) is a lysosomal lipid storage disease (see this term) characterized by variable clinical signs, depending on the age of onset, such as prolonged unexplained neonatal jaundice or cholestasis, isolated unexplained splenomegaly, and progressive, often severe neurological symptoms such as cognitive decline, cerebellar ataxia, vertical supranuclear gaze palsy (VSPG), dysarthria, dysphagia, dystonia, seizures, gelastic cataplexy, and psychiatric disorders.Visit the Orphanet disease page for more resources.

KEGG : 37
Niemann-Pick disease type C is an autosomal recessive lysosomal lipid storage disorder caused by a defect of NPC1 or NPC2 involved in cholesterol trafficking. The disease is characterized by neurodegeneration starting from early life. While NPC1 is a lysosomal transmembrane protein involved in shuttling of substrates to the Golgi and possibly elsewhere in cells, NPC2 is a soluble lysosomal protein known to bind cholesterol.

UniProtKB/Swiss-Prot : 74 Niemann-Pick disease C1: A lysosomal storage disorder that affects the viscera and the central nervous system. It is due to defective intracellular processing and transport of low-density lipoprotein derived cholesterol. It causes accumulation of cholesterol in lysosomes, with delayed induction of cholesterol homeostatic reactions. Niemann-Pick disease type C1 has a highly variable clinical phenotype. Clinical features include variable hepatosplenomegaly and severe progressive neurological dysfunction such as ataxia, dystonia and dementia. The age of onset can vary from infancy to late adulthood. An allelic variant of Niemann-Pick disease type C1 is found in people with Nova Scotia ancestry. Patients with the Nova Scotian clinical variant are less severely affected.

Wikipedia : 75 Niemann-Pick type C (NPC) is a lysosomal storage disease associated with mutations in NPC1 and NPC2... more...

GeneReviews: NBK1296

Related Diseases for Niemann-Pick Disease, Type C1

Diseases in the Niemann-Pick Disease family:

Niemann-Pick Disease, Type a Niemann-Pick Disease, Type C1
Niemann-Pick Disease, Type B Niemann-Pick Disease, Type C2

Diseases related to Niemann-Pick Disease, Type C1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 236)
# Related Disease Score Top Affiliating Genes
1 niemann-pick disease, type c2 33.0 SMPD1 NPC2 NPC1L1 NPC1
2 niemann-pick disease 32.6 SMPD1 PSAP NPC2 NPC1L1 NPC1 APOD
3 acid sphingomyelinase deficiency 32.6 SMPD1 NPC1
4 niemann-pick disease type c, juvenile neurologic onset 32.3 NPC2 NPC1
5 niemann-pick disease type c, adult neurologic onset 32.3 NPC2 NPC1
6 lipid storage disease 32.2 SMPD1 PSAP NPC2 NPC1
7 niemann-pick disease type c, severe early infantile neurologic onset 32.2 NPC2 NPC1
8 niemann-pick disease type c, late infantile neurologic onset 32.2 NPC2 NPC1
9 niemann-pick disease type c, severe perinatal form 32.1 NPC2 NPC1
10 niemann-pick disease, type b 31.8 SMPD1 NPC2 NPC1 ABCA1
11 sphingolipidosis 31.3 SMPD1 PSAP NPC2 NPC1 ASAH2
12 niemann-pick disease, type a 30.7 SMPD1 NPC2 NPC1
13 mucolipidosis ii alpha/beta 30.1 SMPD1 PSAP
14 sandhoff disease 11.6
15 mucolipidosis 11.6
16 ebola hemorrhagic fever 11.5
17 tangier disease 11.4
18 dementia 11.4
19 dystonia 11.4
20 nasopharyngeal carcinoma 11.2
21 headache 11.2
22 inherited metabolic disorder 11.1
23 supranuclear ocular palsy 11.0
24 dysphagia 10.8
25 gaucher's disease 10.7
26 lysosomal storage disease 10.7
27 hypotonia 10.6
28 gaucher disease, type i 10.6
29 tremor 10.6
30 ataxia and polyneuropathy, adult-onset 10.5
31 aceruloplasminemia 10.5
32 crohn's disease 10.5
33 splenomegaly 10.5
34 aspiration pneumonia 10.5
35 narcolepsy 10.5
36 myoclonus 10.5
37 spasticity 10.5
38 autosomal recessive disease 10.4
39 alzheimer disease 10.4
40 respiratory failure 10.4
41 movement disease 10.4
42 peripheral nervous system disease 10.4
43 neuropathy 10.4
44 cerebral atrophy 10.4
45 prader-willi syndrome 10.3
46 hemochromatosis, neonatal 10.3
47 hemochromatosis, type 1 10.3
48 norrie disease 10.3
49 rickets 10.3
50 bronchopneumonia 10.3

Graphical network of the top 20 diseases related to Niemann-Pick Disease, Type C1:



Diseases related to Niemann-Pick Disease, Type C1

Symptoms & Phenotypes for Niemann-Pick Disease, Type C1

Human phenotypes related to Niemann-Pick Disease, Type C1:

59 32 (show all 40)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ataxia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001251
2 gait disturbance 59 32 hallmark (90%) Very frequent (99-80%) HP:0001288
3 developmental regression 59 32 hallmark (90%) Very frequent (99-80%) HP:0002376
4 global developmental delay 59 32 hallmark (90%) Very frequent (99-80%) HP:0001263
5 hepatomegaly 59 32 very rare (1%) Very frequent (99-80%) HP:0002240
6 cognitive impairment 59 32 hallmark (90%) Very frequent (99-80%) HP:0100543
7 dystonia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001332
8 jaundice 59 32 hallmark (90%) Very frequent (99-80%) HP:0000952
9 dysarthria 59 32 frequent (33%) Frequent (79-30%) HP:0001260
10 dysphonia 59 32 frequent (33%) Frequent (79-30%) HP:0001618
11 dysphagia 59 32 frequent (33%) Frequent (79-30%) HP:0002015
12 sleep disturbance 59 32 frequent (33%) Frequent (79-30%) HP:0002360
13 splenomegaly 59 32 very rare (1%) Frequent (79-30%) HP:0001744
14 aplasia/hypoplasia of the abdominal wall musculature 59 32 frequent (33%) Frequent (79-30%) HP:0010318
15 seizures 59 32 very rare (1%) Occasional (29-5%) HP:0001250
16 tremor 59 32 occasional (7.5%) Occasional (29-5%) HP:0001337
17 chorea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002072
18 abnormal pyramidal sign 59 32 occasional (7.5%) Occasional (29-5%) HP:0007256
19 ascites 59 32 occasional (7.5%) Occasional (29-5%) HP:0001541
20 intellectual disability 32 HP:0001249
21 muscular hypotonia 32 HP:0001252
22 spasticity 32 HP:0001257
23 neurological speech impairment 59 Frequent (79-30%)
24 behavioral abnormality 59 Frequent (79-30%)
25 generalized hypotonia 32 HP:0001290
26 psychosis 32 HP:0000709
27 dementia 32 HP:0000726
28 prolonged neonatal jaundice 32 HP:0006579
29 neurofibrillary tangles 32 HP:0002185
30 neuronal loss in central nervous system 32 HP:0002529
31 loss of speech 32 HP:0002371
32 vertical supranuclear gaze palsy 32 HP:0000511
33 fetal ascites 32 HP:0001791
34 sea-blue histiocytosis 32 HP:0001982
35 fatal liver failure in infancy 32 HP:0006583
36 bone-marrow foam cells 32 HP:0004333
37 cataplexy 32 HP:0002524
38 abnormal circulating cholesterol concentration 32 HP:0003107
39 low cholesterol esterification rate 32 HP:0003349
40 foam cells in visceral organs and cns 32 HP:0003640

Symptoms via clinical synopsis from OMIM:

57
Neurologic Central Nervous System:
seizures
spasticity
dysarthria
dystonia
dementia
more
Abdomen Spleen:
splenomegaly

Neurologic Behavioral Psychiatric Manifestations:
psychosis
behavioral problems
poor school performance

Prenatal Manifestations:
fetal ascites

Hematology:
foam cells on bone marrow biopsy
'sea-blue' histiocytes

Abdomen Gastrointestinal:
dysphagia

Abdomen Liver:
hepatomegaly
neonatal jaundice
fatal liver failure in infancy (occasional)

Head And Neck Eyes:
vertical supranuclear gaze palsy

Laboratory Abnormalities:
foam cells in visceral organs and cns
normal or mildly reduced sphingomyelinase activity
low cholesterol esterification rates
abnormal cholesterol homeostasis
foam cells contain polymorphic cytoplasmic inclusions consisting of lamellar osmiophilic membranes on electron microscopy

Clinical features from OMIM:

257220

UMLS symptoms related to Niemann-Pick Disease, Type C1:


seizures, muscle spasticity, cerebellar ataxia

MGI Mouse Phenotypes related to Niemann-Pick Disease, Type C1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.02 APOD APP HCRT MTCL1 NPC1 NPC2
2 growth/size/body region MP:0005378 10.02 ABCA1 APP HCRT MTCL1 NPC1 NPC1L1
3 homeostasis/metabolism MP:0005376 10 ABCA1 APOD APP ASAH2 HCRT NPC1
4 nervous system MP:0003631 9.65 ABCA1 APOD APP HCRT MTCL1 NPC1
5 liver/biliary system MP:0005370 9.63 ABCA1 NPC1 NPC1L1 NPC2 PSAP SMPD1
6 respiratory system MP:0005388 9.17 ABCA1 HCRT NPC1 NPC2 OMP PSAP

Drugs & Therapeutics for Niemann-Pick Disease, Type C1

Drugs for Niemann-Pick Disease, Type C1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miglustat Approved Phase 4 72599-27-0 51634
2
1-Deoxynojirimycin Investigational Phase 4 19130-96-2 1374
3 Anti-Infective Agents Phase 4
4 Antiviral Agents Phase 4
5 Glycoside Hydrolase Inhibitors Phase 4
6 Cardiac Glycosides Phase 4
7 Anti-HIV Agents Phase 4
8 Hypoglycemic Agents Phase 4
9 Anti-Retroviral Agents Phase 4
10
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
11
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
12
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
13
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
14
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
15 Prednisolone acetate Phase 2, Phase 3
16 Methylprednisolone Acetate Phase 2, Phase 3
17 Antilymphocyte Serum Phase 2, Phase 3
18 Pharmaceutical Solutions Phase 2, Phase 3
19
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
20
Acetylcysteine Approved, Investigational Phase 1, Phase 2 616-91-1 12035
21
Lithium carbonate Approved Phase 1, Phase 2 554-13-2
22
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
23
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
24
Itraconazole Approved, Investigational Phase 1, Phase 2 84625-61-6 55283
25
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
26
Busulfan Approved, Investigational Phase 2 55-98-1 2478
27
alemtuzumab Approved, Investigational Phase 2 216503-57-0
28
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
29
Betadex Experimental Phase 1, Phase 2 7585-39-9 320761
30
Emodepside Investigational, Vet_approved Phase 1, Phase 2 155030-63-0
31 Histone Deacetylase Inhibitors Phase 1, Phase 2
32 N-monoacetylcystine Phase 1, Phase 2
33 Antidotes Phase 1, Phase 2
34 Respiratory System Agents Phase 1, Phase 2
35 Free Radical Scavengers Phase 1, Phase 2
36 Antioxidants Phase 1, Phase 2
37 Protective Agents Phase 1, Phase 2
38 cysteine Phase 1, Phase 2
39 Expectorants Phase 1, Phase 2
40 Tranquilizing Agents Phase 1, Phase 2
41 Antidepressive Agents Phase 1, Phase 2
42 Antimanic Agents Phase 1, Phase 2
43 Central Nervous System Depressants Phase 1, Phase 2
44 Psychotropic Drugs Phase 1, Phase 2
45 Liver Extracts Phase 1, Phase 2
46 Antiparasitic Agents Phase 1, Phase 2
47
Bilirubin Phase 1, Phase 2 635-65-4, 69853-43-6 5280352 21252250
48 leucine Phase 2
49 14-alpha Demethylase Inhibitors Phase 1, Phase 2
50 Cytochrome P-450 CYP3A Inhibitors Phase 1, Phase 2

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 A Single Arm Uncontrolled 12 Months Clinical Study to Evaluate the Safety and Efficacy of Miglustat (Zavesca) for the Treatment of Niemann Pick Type C Disease (NPC) in Chinese Subjects Not yet recruiting NCT03910621 Phase 4 Miglustat
2 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
3 Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Bone Marrow Transplantation Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
4 A Phase 2b/3 Prospective, Randomized, Double-Blind, Sham-Controlled 3-Part Trial of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Subjects With Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) Disease Active, not recruiting NCT02534844 Phase 2, Phase 3 VTS-270;Sham Procedure Control
5 Arimoclomol Prospective Doubleblind, Randomised, Placebo-controlled Study in Patients Diagnosed With NiemannPick Disease Type C Active, not recruiting NCT02612129 Phase 2, Phase 3 arimoclomol;Placebo
6 A Phase 2/3, Multicenter, Randomized, Double-blinded, Placebo-controlled, Repeat-dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Active, not recruiting NCT02004691 Phase 2, Phase 3 placebo (saline);GZ402665
7 A Phase 2b/3 Open-label Trial of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Subjects With Neurologic Manifestations of Niemann-Pick Type C1 Disease Previously Treated Under Protocol VTS301 Not yet recruiting NCT03879655 Phase 2, Phase 3 VTS-270
8 Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 Completed NCT02124083 Phase 1, Phase 2 Vorinostat
9 Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine Completed NCT00975689 Phase 1, Phase 2 N-Acetyl Cysteine
10 A Phase II Randomized Controlled Study of Miglustat in Adult and Juvenile Patients With Niemann-Pick Type C Disease Completed NCT00517153 Phase 2 miglustat
11 Phase I/II Trial Of Hematopoietic Stem Cell Transplant (HSCT) For Children With A Genetic Disease Of Blood Cells Without An HLA-Matched Sibling Donor Completed NCT00730314 Phase 1, Phase 2
12 a Single-center, Prospective, Open, and Non-randomized Case-control Study of Lithium Carbonate Effect on Niemann Disease C1 Type Recruiting NCT03201627 Phase 1, Phase 2 Lithium Carbonate
13 Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1 Recruiting NCT03887533 Phase 1, Phase 2 VTS-270
14 Phase 1/2a Study of 2-Hydroxypropyl-Beta-Cyclodextrin Therapy for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C Recruiting NCT03471143 Phase 1, Phase 2 2-Hydroxypropyl-Beta-Cyclodextrin
15 A Phase I/II Study to Evaluate the Safety and PK of iv Trappsol Cyclo (HP-β-CD) in Patients With Niemann-Pick Disease Type C NPC-1 and the Pharmacodynamic Effects of Treatment Upon Markers of Cholesterol Metabolism and Clinical Outcomes Recruiting NCT02912793 Phase 1, Phase 2 Hydroxypropyl-beta-cyclodextrin
16 Effects of N-Acetyl-L-Leucine on Niemann Pick Type C Disease: A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study. Recruiting NCT03759639 Phase 2 IB1001
17 A Phase I/II Study of Hydroxychloroquine and Itraconazole as Therapy for Men With Androgen Normalised Prostate Cancer Recruiting NCT03513211 Phase 1, Phase 2 SUBA-itraconazole;Hydroxychloroquine
18 Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders Active, not recruiting NCT01372228 Phase 1, Phase 2
19 A Phase 1/2, Multi-Center, Open-Label, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Exploratory Efficacy of Olipudase Alfa in Pediatric Patients Aged <18 Years With Acid Sphingomyelinase Deficiency Active, not recruiting NCT02292654 Phase 1, Phase 2 Olipudase alfa
20 A Long-Term Study to Assess the Ongoing Safety and Efficacy of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Enrolling by invitation NCT02004704 Phase 2 GZ402665
21 An Open-label, Multicenter Safety and Tolerability Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Pediatric Subjects Aged < 4 Years With Neurologic Manifestations of Niemann-Pick Type C (NPC) Disease Not yet recruiting NCT03687476 Phase 2 VTS-270
22 Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Hematopoietic Cell Transplantation Terminated NCT00668564 Phase 2 Cyclophosphamide;Campath-1H;Busulfan
23 Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease Completed NCT01747135 Phase 1 VTS-270
24 An Open-label, Multicenter, Ascending Dose Study of the Tolerability and Safety of Recombinant Human Acid Sphingomyelinase (rhASM) in Patients With Acid Sphingomyelinase Deficiency (ASMD) Completed NCT01722526 Phase 1 Recombinant human acid sphingomyelinase
25 A Phase I/II Randomized, Controlled Study of OGT 918 in Adult and Juvenile Patients With Niemann Pick C Disease Completed NCT00316498 Phase 1 OGT918
26 A Phase I Study to Evaluate the Single and Multiple-dose Pharmacokinetics of Intravenous Trappsol Cyclo (HP-Beta-CD) in Patients With Niemann-Pick Disease Type C (NPC-1) and the Effects of Dosing Upon Biomarkers of NPC Disease Recruiting NCT02939547 Phase 1 Hydroxypropyl-beta-cyclodextrin
27 An Open‐Label Extension Study of the Long‐Term Safety and Efficacy of Intravenous Trappsol® Cyclo (HP‐β‐CD) in Patients With Niemann‐Pick Disease Type C (NPC‐1) Recruiting NCT03893071 Phase 1 Hydroxypropyl-β-cyclodextrin
28 Augmentation of Umbilical Cord Blood Transplantation for Inherited Metabolic Diseases With Intrathecal Administration of Human Umbilical Cord Blood-Derived Oligodendrocyte-Like Cells Recruiting NCT02254863 Phase 1
29 A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders Active, not recruiting NCT01586455 Phase 1 Human Placental Derived Stem Cell
30 A Phase I, Single-Center, Single Dose, Dose Escalation Study of Recombinant Human Acid Sphingomyelinase (rhASM) in Adults With Acid Sphingomyelinase Deficiency (ASMD) Terminated NCT00410566 Phase 1 rhASM;rhASM;rhASM;rhASM;rhASM
31 Investigating Lysosomal Storage Diseases in Minority Groups Unknown status NCT02120235
32 Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Unknown status NCT00005900
33 Longitudinal Study of Cognition With Niemann-Pick Disease, Type C Completed NCT01899950
34 A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C in Order to Characterise the Individual Patient Disease Profile and Historic Signo-symptomatology Progression Pattern Completed NCT02435030
35 Positron Emission Tomography Imaging of Human Brain Phospholipid Metabolism in Relation to Age and Disease Completed NCT00001972 15 O Water
36 Induced Pluripotent Stem Cells for the Development of Novel Drug Therapies for Hepatic and Neurological Niemann Pick Disease Recruiting NCT03883750
37 Biomarker for Niemann Pick Type C Disease (NPC1/NPC2) an International, Multicenter, Epidemiological Study Recruiting NCT01306604
38 Investigations Into Inborn Errors of Cholesterol Synthesis and Related Disorders Recruiting NCT00046202
39 Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C Recruiting NCT00344331
40 Longitudinal Study of Neurodegenerative Disorders Recruiting NCT03333200
41 Genetic Characterization of Movement Disorders and Dementias Recruiting NCT02014246
42 An Open-label Expanded Access Treatment Protocol for VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Patients With Neurologic Manifestations of Niemann-Pick Type C Disease (NPC) Available NCT03643562 VTS270
43 Study Qbout the Screening of Niemann-Pick Disease, Type C in a Psychiatric Population Terminated NCT02841358

Search NIH Clinical Center for Niemann-Pick Disease, Type C1

Cochrane evidence based reviews: niemann-pick disease, type c

Genetic Tests for Niemann-Pick Disease, Type C1

Genetic tests related to Niemann-Pick Disease, Type C1:

# Genetic test Affiliating Genes
1 Niemann-Pick Disease, Type C 29
2 Niemann-Pick Disease Type C1 29 NPC1
3 Niemann-Pick Disease, Type D 29

Anatomical Context for Niemann-Pick Disease, Type C1

MalaCards organs/tissues related to Niemann-Pick Disease, Type C1:

41
Liver, Brain, Bone, Bone Marrow, Skin, Eye, Spleen

Publications for Niemann-Pick Disease, Type C1

Articles related to Niemann-Pick Disease, Type C1:

(show top 50) (show all 766)
# Title Authors PMID Year
1
NPC1 gene mutations in Japanese patients with Niemann-Pick disease type C. 9 38 4 8 71
10480349 1999
2
Heterozygous Niemann-Pick disease type C presenting with tremor. 38 4 8 71
15596783 2004
3
Niemann-Pick C variant detection by altered sphingolipid trafficking and correlation with mutations within a specific domain of NPC1. 38 4 8 71
11349231 2001
4
The Nova Scotia (type D) form of Niemann-Pick disease is caused by a G3097-->T transversion in NPC1. 9 4 8 71
9634529 1998
5
Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. 4 8 71
9211849 1997
6
Niemann-Pick disease type C: spectrum of HE1 mutations and genotype/phenotype correlations in the NPC2 group. 9 38 4 71
11567215 2001
7
Linkage of Niemann-Pick disease type D to the same region of human chromosome 18 as Niemann-Pick disease type C. 38 8 71
9245994 1997
8
White and gray matter alterations in adults with Niemann-Pick disease type C: a cross-sectional study. 38 4 8
20484681 2010
9
Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. 38 4 8
18953351 2008
10
Frontal lobe atrophy due to a mutation in the cholesterol binding protein HE1/NPC2. 38 4 71
12447927 2002
11
Niemann-Pick disease type C in adults. 38 4 8
12555942 2002
12
Ultrastructural findings in skin from patients with Niemann-Pick disease, type C. 38 4 8
2360958 1990
13
A defect in cholesterol esterification in Niemann-Pick disease (type C) patients. 38 4 8
3865225 1985
14
A hereditary disorder with dementia, spastic dysarthria, vertical eye movement paresis, gait disturbance, splenomegaly, and abnormal copper metabolism. 8 71
4795418 1973
15
Niemann-Pick C1 disease: correlations between NPC1 mutations, levels of NPC1 protein, and phenotypes emphasize the functional significance of the putative sterol-sensing domain and of the cysteine-rich luminal loop. 4 71
11333381 2001
16
Identification of HE1 as the second gene of Niemann-Pick C disease. 4 71
11125141 2000
17
Genotype-phenotype relationship of Niemann-Pick disease type C: a possible correlation between clinical onset and levels of NPC1 protein in isolated skin fibroblasts. 9 38 8
11182931 2000
18
Niemann-Pick C1 disease: the I1061T substitution is a frequent mutant allele in patients of Western European descent and correlates with a classic juvenile phenotype. 4 71
10521297 1999
19
High incidence of unrecognized visceral/neurological late-onset Niemann-Pick disease, type C1, predicted by analysis of massively parallel sequencing data sets. 38 8
25764212 2016
20
Saccades in adult Niemann-Pick disease type C reflect frontal, brainstem, and biochemical deficits. 38 8
19307542 2009
21
Niemann-Pick C disease: functional characterization of three NPC2 mutations and clinical and molecular update on patients with NPC2. 9 71
17470133 2007
22
Niemann-Pick C disease: use of denaturing high performance liquid chromatography for the detection of NPC1 and NPC2 genetic variations and impact on management of patients and families. 9 38 4
16126423 2005
23
Niemann-Pick type C disease: subcellular location and functional characterization of NPC2 proteins with naturally occurring missense mutations. 9 38 4
15937921 2005
24
Niemann-Pick type C disease: importance of N-glycosylation sites for function and cellular location of the NPC2 protein. 9 38 4
15542393 2004
25
Identification of 58 novel mutations in Niemann-Pick disease type C: correlation with biochemical phenotype and importance of PTC1-like domains in NPC1. 9 38 4
12955717 2003
26
Niemann-Pick disease type C. 38 8
12974729 2003
27
Sleep disturbances and hypocretin deficiency in Niemann-Pick disease type C. 9 38 4
12841368 2003
28
Defective endocytic trafficking of NPC1 and NPC2 underlying infantile Niemann-Pick type C disease. 9 71
12554680 2003
29
Identification of novel mutations in the NPC1 gene in German patients with Niemann-Pick C disease. 38 8
12408188 2002
30
Niemann-Pick type C disease: NPC1 mutations associated with severe and mild cellular cholesterol trafficking alterations. 9 71
11479732 2001
31
Isolated splenomegaly as the presenting feature of Niemann-Pick disease type C. 38 8
11316691 2001
32
Alleviation of neuronal ganglioside storage does not improve the clinical course of the Niemann-Pick C disease mouse. 38 8
10767333 2000
33
Niemann-Pick Disease Type C 38 71
20301473 2000
34
A C57BL/KsJ mouse model of Niemann-Pick disease (spm) belongs to the same complementation group as the major childhood type of Niemann-Pick disease type C. 38 8
9050921 1997
35
Psychosis as the initial manifestation of adult-onset Niemann-Pick disease type C. 38 8
7675237 1995
36
Feline Niemann-Pick disease type C. 38 8
8203477 1994
37
Complementation studies in Niemann-Pick disease type C indicate the existence of a second group. 38 8
8071958 1994
38
Linkage of Niemann-Pick disease type C to human chromosome 18. 38 8
8446622 1993
39
Feline sphingolipidosis resembling Niemann-Pick disease type C. 38 8
2127982 1990
40
Clinical spectrum of Niemann-Pick disease type C. 38 8
2761697 1989
41
Niemann-Pick disease--type C. Ocular histopathologic and electron microscopic studies. 38 8
4004622 1985
42
Clinical heterogeneity in a sibship with Niemann-Pick disease type C. 38 8
6839525 1983
43
Niemann-Pick disease type C. Pathological, histochemical, ultrastructural and biochemical studies. 38 8
7262098 1981
44
Niemann-Pick disease, Type C: evidence for the deficiency of an activating factor stimulating sphingomyelin and glucocerebroside degradation. 38 8
6256275 1980
45
Long-term efficacy of miglustat in paediatric patients with Niemann-Pick disease type C. 38 4
22476655 2013
46
Dysphagia as a risk factor for mortality in Niemann-Pick disease type C: systematic literature review and evidence from studies with miglustat. 38 4
23039766 2012
47
Early miglustat therapy in infantile Niemann-Pick disease type C. 38 4
22704015 2012
48
Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. 38 4
22572546 2012
49
Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C. 38 4
22676771 2012
50
Miglustat improves purkinje cell survival and alters microglial phenotype in feline Niemann-Pick disease type C. 38 4
22487861 2012

Variations for Niemann-Pick Disease, Type C1

ClinVar genetic disease variations for Niemann-Pick Disease, Type C1:

6 (show top 50) (show all 333)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 NPC1 NM_000271.5(NPC1): c.852del (p.Phe284fs) deletion Pathogenic rs762124334 18:21140224-21140224 18:23560260-23560260
2 NPC1 NM_000271.5(NPC1): c.350_351AG[1] (p.Gln119fs) short repeat Pathogenic rs759075595 18:21148897-21148898 18:23568933-23568934
3 NPC1 NM_000271.5(NPC1): c.1421C> T (p.Pro474Leu) single nucleotide variant Pathogenic rs372445155 18:21134854-21134854 18:23554890-23554890
4 NPC1 NM_000271.5(NPC1): c.881+1G> T single nucleotide variant Pathogenic rs1555638409 18:21140194-21140194 18:23560230-23560230
5 NPC1 NM_000271.5(NPC1): c.3517dup (p.Arg1173fs) duplication Pathogenic rs1555631982 18:21114484-21114484 18:23534520-23534520
6 NPC1 NM_000271.5(NPC1): c.1171G> T (p.Glu391Ter) single nucleotide variant Pathogenic rs1555637139 18:21136362-21136362 18:23556398-23556398
7 NPC1 NM_000271.5(NPC1): c.3562del (p.Glu1188fs) deletion Pathogenic rs758231839 18:21114438-21114439 18:23534475-23534475
8 NPC1 NM_000271.5(NPC1): c.1628del (p.Pro543fs) deletion Pathogenic rs1555635957 18:21131616-21131617 18:23551653-23551653
9 NPC1 NM_000271.5(NPC1): c.2783A> C (p.Gln928Pro) single nucleotide variant Pathogenic rs28940897 18:21119787-21119787 18:23539823-23539823
10 NPC1 NPC1, IVS16, G-A, -82 single nucleotide variant Pathogenic
11 NPC1 NM_000271.5(NPC1): c.3182T> C (p.Ile1061Thr) single nucleotide variant Pathogenic rs80358259 18:21116700-21116700 18:23536736-23536736
12 NPC1 NM_000271.5(NPC1): c.2873G> A (p.Arg958Gln) single nucleotide variant Pathogenic rs120074132 18:21119357-21119357 18:23539393-23539393
13 NPC1 NM_000271.5(NPC1): c.1133T> C (p.Val378Ala) single nucleotide variant Pathogenic rs120074134 18:21136400-21136400 18:23556436-23556436
14 NPC1 NM_000271.5(NPC1): c.3662del (p.Phe1221fs) deletion Pathogenic rs786200878 18:21113411-21113411 18:23533447-23533447
15 NPC1 NM_000271.5(NPC1): c.337T> C (p.Cys113Arg) single nucleotide variant Pathogenic rs120074136 18:21148913-21148913 18:23568949-23568949
16 NPC1 NM_000271.5(NPC1): c.3611_3614del (p.Leu1204fs) deletion Pathogenic rs786200879 18:21113459-21113462 18:23533495-23533498
17 NPC2 NM_006432.4(NPC2): c.58G> T (p.Glu20Ter) single nucleotide variant Pathogenic rs80358260 14:74959920-74959920 14:74493217-74493217
18 NPC1 NM_000271.5(NPC1): c.2324A> C (p.Gln775Pro) single nucleotide variant Pathogenic rs80358253 18:21121319-21121319 18:23541355-23541355
19 NPC1 NM_000271.5(NPC1): c.3160G> A (p.Ala1054Thr) single nucleotide variant Pathogenic rs80358258 18:21116722-21116722 18:23536758-23536758
20 NPC1 NM_000271.5(NPC1): c.2196dup (p.Pro733fs) duplication Pathogenic rs398123284 18:21123468-21123468 18:23543504-23543504
21 NPC1 NM_000271.5(NPC1): c.1832A> G (p.Asp611Gly) single nucleotide variant Pathogenic rs483352887 18:21125039-21125039 18:23545075-23545075
22 NPC1 NM_000271.5(NPC1): c.2054T> C (p.Ile685Thr) single nucleotide variant Pathogenic rs483352888 18:21124384-21124384 18:23544420-23544420
23 NPC1 NM_000271.5(NPC1): c.2128C> T (p.Gln710Ter) single nucleotide variant Pathogenic rs483352889 18:21124310-21124310 18:23544346-23544346
24 NPC1 NM_000271.5(NPC1): c.2177G> C (p.Arg726Thr) single nucleotide variant Pathogenic rs483352890 18:21123487-21123487 18:23543523-23543523
25 NPC1 NM_000271.5(NPC1): c.2302dup (p.Val768fs) duplication Pathogenic rs483352881 18:21121341-21121341 18:23541377-23541377
26 NPC1 NM_000271.5(NPC1): c.2366G> A (p.Arg789His) single nucleotide variant Pathogenic rs483352891 18:21121277-21121277 18:23541313-23541313
27 NPC1 NM_000271.5(NPC1): c.2795dup (p.Tyr932Ter) duplication Pathogenic rs483352884 18:21119775-21119775 18:23539811-23539811
28 NPC1 NM_000271.5(NPC1): c.2912-3C> G single nucleotide variant Pathogenic rs483352892 18:21118638-21118638 18:23538674-23538674
29 NPC1 NM_000271.5(NPC1): c.416dup (p.Asn140fs) duplication Pathogenic rs483352880 18:21148834-21148834 18:23568870-23568870
30 NPC1 NM_000271.5(NPC1): c.1030del (p.Ser344fs) deletion Pathogenic rs483352883 18:21136503-21136503 18:23556539-23556539
31 NPC1 NM_000271.5(NPC1): c.1502A> T (p.Asp501Val) single nucleotide variant Pathogenic rs483352885 18:21134773-21134773 18:23554809-23554809
32 NPC1 NM_000271.5(NPC1): c.3234_3237dup (p.Pro1080fs) duplication Pathogenic rs863224902 18:21116645-21116648 18:23536681-23536684
33 NPC1 NM_000271.5(NPC1): c.2213C> A (p.Ser738Ter) single nucleotide variant Pathogenic rs777286835 18:21123451-21123451 18:23543487-23543487
34 NPC1 NM_000271.5(NPC1): c.3127A> G (p.Thr1043Ala) single nucleotide variant Pathogenic rs876661319 18:21116755-21116755 18:23536791-23536791
35 NPC1 NM_000271.5(NPC1): c.3246-2A> G single nucleotide variant Pathogenic rs886042268 18:21115666-21115666 18:23535702-23535702
36 NPC1 NM_000271.5(NPC1): c.1819C> T (p.Arg607Ter) single nucleotide variant Pathogenic rs377130051 18:21125052-21125052 18:23545088-23545088
37 NPC1 NM_000271.5(NPC1): c.2872C> T (p.Arg958Ter) single nucleotide variant Pathogenic rs759826138 18:21119358-21119358 18:23539394-23539394
38 NPC1 NM_000271.5(NPC1): c.3229C> T (p.Arg1077Ter) single nucleotide variant Pathogenic rs750095738 18:21116653-21116653 18:23536689-23536689
39 NPC1 NM_000271.5(NPC1): c.306T> G (p.Tyr102Ter) single nucleotide variant Pathogenic 18:21148944-21148944 18:23568980-23568980
40 NPC1 NM_000271.5(NPC1): c.2096del (p.Val699fs) deletion Pathogenic 18:21124342-21124342 18:23544378-23544378
41 NPC1 NM_000271.5(NPC1): c.2728G> A (p.Gly910Ser) single nucleotide variant Pathogenic/Likely pathogenic rs768999208 18:21119842-21119842 18:23539878-23539878
42 NPC1 NM_000271.5(NPC1): c.1920del (p.His641fs) deletion Pathogenic/Likely pathogenic rs886042270 18:21124951-21124951 18:23544987-23544987
43 NPC1 NM_000271.5(NPC1): c.1142G> A (p.Trp381Ter) single nucleotide variant Pathogenic/Likely pathogenic rs794727897 18:21136391-21136391 18:23556427-23556427
44 NPC1 NM_000271.5(NPC1): c.1553G> A (p.Arg518Gln) single nucleotide variant Pathogenic/Likely pathogenic rs483352886 18:21134722-21134722 18:23554758-23554758
45 NPC1 NM_000271.5(NPC1): c.2861C> T (p.Ser954Leu) single nucleotide variant Pathogenic/Likely pathogenic rs543206298 18:21119369-21119369 18:23539405-23539405
46 NPC1 NM_000271.5(NPC1): c.1628C> T (p.Pro543Leu) single nucleotide variant Pathogenic/Likely pathogenic rs369368181 18:21131617-21131617 18:23551653-23551653
47 NPC1 NM_000271.5(NPC1): c.3614C> A (p.Thr1205Lys) single nucleotide variant Pathogenic/Likely pathogenic rs758902805 18:21113459-21113459 18:23533495-23533495
48 NPC1 NM_000271.5(NPC1): c.3557G> A (p.Arg1186His) single nucleotide variant Pathogenic/Likely pathogenic rs200444084 18:21114444-21114444 18:23534480-23534480
49 NPC1 NM_000271.5(NPC1): c.2819C> T (p.Ser940Leu) single nucleotide variant Pathogenic/Likely pathogenic rs143124972 18:21119411-21119411 18:23539447-23539447
50 NPC1 NM_000271.5(NPC1): c.1211G> A (p.Arg404Gln) single nucleotide variant Pathogenic/Likely pathogenic rs139751448 18:21136322-21136322 18:23556358-23556358

UniProtKB/Swiss-Prot genetic disease variations for Niemann-Pick Disease, Type C1:

74 (show top 50) (show all 150)
# Symbol AA change Variation ID SNP ID
1 NPC1 p.Cys177Gly VAR_008815
2 NPC1 p.Ser473Pro VAR_008820
3 NPC1 p.His510Pro VAR_008821
4 NPC1 p.Arg518Gln VAR_008822 rs483352886
5 NPC1 p.Val889Met VAR_008826 rs120074130
6 NPC1 p.Gln928Pro VAR_008827 rs28940897
7 NPC1 p.Arg934Gln VAR_008828 rs786204714
8 NPC1 p.Ser940Leu VAR_008829 rs143124972
9 NPC1 p.Asp948Asn VAR_008830 rs126193914
10 NPC1 p.Ser954Leu VAR_008831 rs543206298
11 NPC1 p.Cys956Tyr VAR_008832
12 NPC1 p.Gly992Trp VAR_008833 rs80358254
13 NPC1 p.Pro1007Ala VAR_008834 rs80358257
14 NPC1 p.Thr1036Met VAR_008835 rs28942104
15 NPC1 p.Ile1061Thr VAR_008836 rs80358259
16 NPC1 p.Tyr1088Cys VAR_008837 rs28942106
17 NPC1 p.Asn1156Ser VAR_008838 rs28942105
18 NPC1 p.Phe1167Leu VAR_008839
19 NPC1 p.Arg1186His VAR_008840 rs200444084
20 NPC1 p.Leu1213Phe VAR_008841 rs120074131
21 NPC1 p.Leu1213Val VAR_008842 rs766178353
22 NPC1 p.Cys177Tyr VAR_015561 rs80358252
23 NPC1 p.Val378Ala VAR_015562 rs120074134
24 NPC1 p.Val950Met VAR_015563 rs120074135
25 NPC1 p.Arg958Gln VAR_015564 rs120074132
26 NPC1 p.Arg978Cys VAR_015565 rs28942108
27 NPC1 p.Gly992Arg VAR_015566 rs80358254
28 NPC1 p.Ala1035Val VAR_015567 rs28942107
29 NPC1 p.Cys63Arg VAR_043172 rs747049347
30 NPC1 p.Cys74Tyr VAR_043173
31 NPC1 p.Gln92Arg VAR_043174
32 NPC1 p.Cys113Arg VAR_043175 rs120074136
33 NPC1 p.Thr137Met VAR_043176 rs372947142
34 NPC1 p.Pro166Ser VAR_043178 rs866966704
35 NPC1 p.Asn222Ser VAR_043179 rs55680026
36 NPC1 p.Val231Gly VAR_043180
37 NPC1 p.Asp242His VAR_043181
38 NPC1 p.Asp242Asn VAR_043182
39 NPC1 p.Cys247Tyr VAR_043183
40 NPC1 p.Gly248Val VAR_043184 rs123053860
41 NPC1 p.Met272Arg VAR_043185
42 NPC1 p.Arg372Trp VAR_043187 rs134643653
43 NPC1 p.Leu380Phe VAR_043188 rs143591549
44 NPC1 p.Ala388Pro VAR_043190 rs155563715
45 NPC1 p.Arg389Cys VAR_043191 rs105332182
46 NPC1 p.Pro401Thr VAR_043192 rs766301620
47 NPC1 p.Arg404Pro VAR_043193
48 NPC1 p.Arg404Gln VAR_043194 rs139751448
49 NPC1 p.Arg404Trp VAR_043195 rs129823851
50 NPC1 p.Pro433Leu VAR_043196 rs106479379

Expression for Niemann-Pick Disease, Type C1

Search GEO for disease gene expression data for Niemann-Pick Disease, Type C1.

Pathways for Niemann-Pick Disease, Type C1

Pathways related to Niemann-Pick Disease, Type C1 according to KEGG:

37
# Name Kegg Source Accession
1 Lysosome hsa04142

GO Terms for Niemann-Pick Disease, Type C1

Cellular components related to Niemann-Pick Disease, Type C1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.91 SMPD1 PSAP NPC2 NPC1 MIR143 APP
2 extracellular region GO:0005576 9.76 SMPD1 PSAP NPC2 NPC1 HCRT ASAH2
3 perinuclear region of cytoplasm GO:0048471 9.65 NPC1 HCRT APP APOD ABCA1
4 lysosome GO:0005764 9.62 SMPD1 PSAP NPC2 NPC1
5 extracellular space GO:0005615 9.23 SMPD1 PSAP NPC2 MTCL1 MIR98 MIR143
6 lysosomal lumen GO:0043202 9.13 SMPD1 PSAP NPC2

Biological processes related to Niemann-Pick Disease, Type C1 according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.83 SMPD1 NPC1L1 NPC1 APOD ABCA1
2 lipid metabolic process GO:0006629 9.8 PSAP NPC2 NPC1L1 NPC1 ASAH2 APOD
3 steroid metabolic process GO:0008202 9.71 NPC2 NPC1L1 NPC1 ABCA1
4 cholesterol homeostasis GO:0042632 9.65 NPC2 NPC1 ABCA1
5 regulation of autophagy GO:0010506 9.63 RMC1 PSAP MTCL1
6 glycosphingolipid metabolic process GO:0006687 9.55 SMPD1 PSAP
7 cholesterol metabolic process GO:0008203 9.55 NPC2 NPC1L1 NPC1 APP ABCA1
8 negative regulation of smooth muscle cell proliferation GO:0048662 9.54 MIR143 APOD
9 cholesterol efflux GO:0033344 9.54 NPC2 NPC1 ABCA1
10 low-density lipoprotein particle clearance GO:0034383 9.52 NPC2 NPC1
11 lipoprotein metabolic process GO:0042157 9.51 NPC1L1 ABCA1
12 intracellular cholesterol transport GO:0032367 9.5 NPC2 NPC1 ABCA1
13 cellular response to low-density lipoprotein particle stimulus GO:0071404 9.49 NPC1 ABCA1
14 cholesterol transport GO:0030301 9.26 NPC2 NPC1L1 NPC1 ABCA1
15 lipid transport GO:0006869 9.1 PSAP NPC2 NPC1L1 NPC1 APOD ABCA1

Molecular functions related to Niemann-Pick Disease, Type C1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cholesterol transporter activity GO:0017127 9.16 NPC2 ABCA1
2 lipid transporter activity GO:0005319 9.13 NPC1 APOD ABCA1
3 cholesterol binding GO:0015485 8.92 NPC2 NPC1 APOD ABCA1

Sources for Niemann-Pick Disease, Type C1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....